VAS-2870

NADPH oxidase inhibitor



BML-EI395-0010	10 mg	93.00 USD

BML-EI395-0050	50 mg	371.00 USD

Novel inhibitor of NAD(P)H oxidase (Nox). In vascular smooth muscle cells VAS-2870 completely abolished PDGF-mediated NAD(P)H oxidase activation and ROS production (100% at 10µM). It inhibits PDGF-induced chemotaxis but not proliferation of VSMC. In mouse embryonic stem cells VAS-2870 blocked PDGF-BB-induced vasculogenesis. OxLDL-induced ROS formation in human endothelial cells was completely inhibited by VAS-2870 (100% at 5µM). VAS-2870 inhibits PMS-induced oxidative burst in HL-60 cells (IC₅₀=2µM).

Product Specification

Alternative Name:	3-Benzyl-7-(2-benzoxazolyl)thio-1,2,3-triazolo(4,5-d)pyrimidine

Formula:	C₁₈H₁₂N₆OS

MW:	360.4

Purity:	≥98% (TLC)

Appearance:	Off-white solid.

CAS:	722456-31-7

Solubility:	Soluble in DMSO (10mg/ml) or DMF (>25mg/ml).

Long Term Storage:	+20°C

Use/Stability:	Store solutions at -20°C for up to 3 months.

Background / Technical Information:	Please click here for the comprehensive product data sheet.

Please mouse over

Product Literature References

Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species: S. Lange, et al.; Cardiovasc. Res. 81, 159 (2009), Abstract;

Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells: C. Stielow, et al.; BBRC 344, 200 (2006), Abstract;

Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation: H. ten Freyhaus, et al.; Cardiovasc. Res. 71, 331 (2006), Abstract;